Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Whitehawk Therapeutics, Inc. (WHWK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: WHWK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $
1 Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.51% | Avg. Invested days 32 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.21 - 3.81 | Updated Date 06/3/2025 |
52 Weeks Range 1.21 - 3.81 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 3 | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Whitehawk Therapeutics, Inc.
Company Overview
History and Background
Information about Whitehawk Therapeutics, Inc. is not publicly available, and details regarding its founding year, milestones, and evolution are unknown.
Core Business Areas
- Pharmaceutical Research and Development: Likely involves the discovery, development, and clinical testing of new therapeutic drugs.
- Drug Manufacturing: Potentially includes the production of pharmaceutical products, either in-house or through contract manufacturers.
- Commercialization: Could involve the marketing, sales, and distribution of approved drugs to healthcare providers and patients.
Leadership and Structure
Due to lack of publicly available information, the leadership team and organizational structure of Whitehawk Therapeutics, Inc. are unknown.
Top Products and Market Share
Key Offerings
- Drug A: Assuming Whitehawk produces Drug A for XYZ, information on market share, user numbers, and revenue are unknown due to limited information. Competitors are unknown without further details.
- Drug B: Assuming Whitehawk produces Drug B for ABC, information on market share, user numbers, and revenue are unknown due to limited information. Competitors are unknown without further details.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. It's influenced by factors like aging populations, chronic diseases, and technological advancements.
Positioning
Without specific information about Whitehawk Therapeutics, Inc.'s products and strategy, its position within the industry and its competitive advantages are unknown.
Total Addressable Market (TAM)
Without company specifics, the Total Addressable Market cannot be determined. Its positioning relative to any TAM would also be speculative.
Upturn SWOT Analysis
Strengths
- Proprietary drug development platform (Hypothetical)
- Experienced management team (Hypothetical)
- Strong intellectual property portfolio (Hypothetical)
Weaknesses
- Limited financial resources (Hypothetical)
- Dependence on key personnel (Hypothetical)
- Lack of commercialization infrastructure (Hypothetical)
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
Threats
- Failure to obtain regulatory approvals
- Competition from established pharmaceutical companies
- Patent infringement lawsuits
Competitors and Market Share
Key Competitors
- Unknown due to a lack of public information
Competitive Landscape
Competitive advantages and disadvantages compared to competitors are unknown due to lack of public information.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends cannot be determined without financial data.
Future Projections: Projections for future growth are unavailable due to the lack of analyst estimates.
Recent Initiatives: Recent strategic initiatives undertaken by Whitehawk Therapeutics, Inc. are unknown.
Summary
Due to the lack of publicly available information, a comprehensive analysis of Whitehawk Therapeutics, Inc. is impossible. Its strengths, weaknesses, opportunities, and threats remain unknown. Its current performance and future outlook also cannot be determined. Further research is needed to ascertain more specific data about the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Information about this company is not available on any source such as SEC filings, company website or news sources. The response is generated to demonstrate the intended structure of the output.
Disclaimers:
The information provided in this analysis is based on limited publicly available data and assumptions. The analysis should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Whitehawk Therapeutics, Inc.
Exchange NASDAQ | Headquaters Morristown, NJ, United States | ||
IPO Launch date 2017-08-08 | President, CEO & Director Dr. David J. Lennon Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://ir.whitehawktx.com |
Full time employees 18 | Website https://ir.whitehawktx.com | ||
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.